RU2639540C2 - Способы и композиции для лечения аутоиммунных и воспалительных заболеваний - Google Patents

Способы и композиции для лечения аутоиммунных и воспалительных заболеваний Download PDF

Info

Publication number
RU2639540C2
RU2639540C2 RU2014106933A RU2014106933A RU2639540C2 RU 2639540 C2 RU2639540 C2 RU 2639540C2 RU 2014106933 A RU2014106933 A RU 2014106933A RU 2014106933 A RU2014106933 A RU 2014106933A RU 2639540 C2 RU2639540 C2 RU 2639540C2
Authority
RU
Russia
Prior art keywords
antibody
rhob
inflammatory
seq
antibodies
Prior art date
Application number
RU2014106933A
Other languages
English (en)
Russian (ru)
Other versions
RU2014106933A (ru
Inventor
Лиза ЛАУРИ-КЛЕЙНТОП
Лаура МАНДИК-НАЯК
Джордж С. ПРЕНДЕРГАСТ
Джеймс ДУХАДАУЭЙ
Original Assignee
Ланкенау Инститьют Фо Медикал Ресёрч
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ланкенау Инститьют Фо Медикал Ресёрч filed Critical Ланкенау Инститьют Фо Медикал Ресёрч
Publication of RU2014106933A publication Critical patent/RU2014106933A/ru
Application granted granted Critical
Publication of RU2639540C2 publication Critical patent/RU2639540C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/40—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Candida
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
RU2014106933A 2011-08-10 2012-08-09 Способы и композиции для лечения аутоиммунных и воспалительных заболеваний RU2639540C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161522009P 2011-08-10 2011-08-10
US61/522,009 2011-08-10
PCT/US2012/050146 WO2013023059A2 (en) 2011-08-10 2012-08-09 Methods and compositions for the treatment of autoimmune and inflammatory diseases

Publications (2)

Publication Number Publication Date
RU2014106933A RU2014106933A (ru) 2015-09-20
RU2639540C2 true RU2639540C2 (ru) 2017-12-21

Family

ID=47669232

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014106933A RU2639540C2 (ru) 2011-08-10 2012-08-09 Способы и композиции для лечения аутоиммунных и воспалительных заболеваний

Country Status (10)

Country Link
US (3) US9879092B2 (enExample)
EP (1) EP2741771B1 (enExample)
JP (1) JP6253580B2 (enExample)
KR (2) KR102221068B1 (enExample)
CN (1) CN104114184B (enExample)
AU (1) AU2012294342B2 (enExample)
CA (1) CA2844668C (enExample)
ES (1) ES2813415T3 (enExample)
RU (1) RU2639540C2 (enExample)
WO (1) WO2013023059A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
WO2013023059A2 (en) 2011-08-10 2013-02-14 Lankenau Institute For Medical Research Methods and compositions for the treatment of autoimmune and inflammatory diseases
CA2884704C (en) 2012-09-07 2023-04-04 Randolph J. Noelle Vista modulators for diagnosis and treatment of cancer
US10273301B2 (en) 2013-12-24 2019-04-30 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
AU2015243261B2 (en) * 2014-04-10 2020-06-25 Lankenau Institute For Medical Research Methods and compositions for the treatment of ocular diseases and disorders
EP3722314A1 (en) 2015-06-24 2020-10-14 Janssen Pharmaceutica NV Anti-vista antibodies and fragments
US10899836B2 (en) 2016-02-12 2021-01-26 Janssen Pharmaceutica Nv Method of identifying anti-VISTA antibodies
PE20190115A1 (es) 2016-04-15 2019-01-16 Immunext Inc Anticuerpos vista antihumanos y su uso
WO2018213331A1 (en) * 2017-05-16 2018-11-22 Lankenau Institute For Medical Research Compositions comprising ligands to rhob protein and the uses thereof
KR102276941B1 (ko) * 2018-07-03 2021-07-14 서울대학교산학협력단 류마티스 관절염 치료용 펩티드 및 그의 용도

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962672A (en) * 1998-09-18 1999-10-05 Isis Pharmaceuticals Inc. Antisense modulation of RhoB expression
US20050142103A1 (en) * 2003-08-13 2005-06-30 Williams David A. Mobilization of hematopoietic cells
RU2008140661A (ru) * 2006-04-09 2010-04-20 Джинентех, Инк. (US) Применение антитела для лечения аутоиммунных заболеваний у пациента с неадекватным ответом на ингибитор tnf-альфа

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4116793A (en) * 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
EP1027042A4 (en) 1997-09-29 2004-08-18 Bristol Myers Squibb Co FARNESYL PROTEIN TRANSFERASE INHIBITORS
US6458783B1 (en) * 1997-09-29 2002-10-01 Bristol-Myers Squibb Company Non-imidazole benzodiazepine inhibitors of farnesyl protein transferase
US20050032733A1 (en) 2001-05-18 2005-02-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)
US6979556B2 (en) 2000-12-14 2005-12-27 Genentech, Inc. Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
US7795218B2 (en) 2001-04-12 2010-09-14 Bioaxone Therapeutique Inc. ADP-ribosyl transferase fusion variant proteins
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
EP1537140B1 (en) 2001-11-07 2013-01-02 Agensys, Inc. Nucleic acid and corresponding protein entitled 161p2f10b useful in treatment and detection of cancer
JP4967137B2 (ja) * 2005-04-18 2012-07-04 国立大学法人浜松医科大学 癌治療用組成物
US20070213354A1 (en) * 2006-03-08 2007-09-13 Amplimed Corporation Compositions and Methods for the Treatment of Multiple Sclerosis
JP5354634B2 (ja) * 2007-01-25 2013-11-27 国立大学法人大阪大学 ヒトａｂｈ８タンパク質、それをコードする遺伝子、およびこれらの治療的又は診断的用途
EP2221063A1 (en) * 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer
JP5941841B2 (ja) * 2009-05-26 2016-06-29 アイカーン スクール オブ メディシン アット マウント サイナイ 周期的投与によって作製されたインフルエンザウイルスに対するモノクローナル抗体及びその使用
WO2013004551A1 (en) 2011-07-01 2013-01-10 Bayer Intellectual Property Gmbh Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors
WO2013023059A2 (en) 2011-08-10 2013-02-14 Lankenau Institute For Medical Research Methods and compositions for the treatment of autoimmune and inflammatory diseases
TW201406707A (zh) 2012-05-04 2014-02-16 Acucela Inc 用以治療糖尿病性視網膜病變及其他眼部疾病之方法
AU2015243261B2 (en) * 2014-04-10 2020-06-25 Lankenau Institute For Medical Research Methods and compositions for the treatment of ocular diseases and disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962672A (en) * 1998-09-18 1999-10-05 Isis Pharmaceuticals Inc. Antisense modulation of RhoB expression
US20050142103A1 (en) * 2003-08-13 2005-06-30 Williams David A. Mobilization of hematopoietic cells
RU2008140661A (ru) * 2006-04-09 2010-04-20 Джинентех, Инк. (US) Применение антитела для лечения аутоиммунных заболеваний у пациента с неадекватным ответом на ингибитор tnf-альфа

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HAQUE S. et al. Atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus, Curr Opin Lipidol, 2008, Vol.19, N.4, pp.338-343. *
HAQUE S. et al. Atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus, Curr Opin Lipidol, 2008, Vol.19, N.4, pp.338-343. WANG L. et al. A Novel Strategy for Specifically Down-regulating Individual Rho GTPase Activity in Tumor Cells, The Journal of Biological Chemistry, 2003, Vol.278, p.44617-44625. *
WANG L. et al. A Novel Strategy for Specifically Down-regulating Individual Rho GTPase Activity in Tumor Cells, The Journal of Biological Chemistry, 2003, Vol.278, p.44617-44625. *

Also Published As

Publication number Publication date
KR20200042013A (ko) 2020-04-22
KR102101478B1 (ko) 2020-04-16
JP2014529590A (ja) 2014-11-13
EP2741771B1 (en) 2020-04-29
EP2741771A2 (en) 2014-06-18
EP2741771A4 (en) 2015-04-15
AU2012294342A1 (en) 2014-03-06
WO2013023059A2 (en) 2013-02-14
JP6253580B2 (ja) 2017-12-27
ES2813415T3 (es) 2021-03-23
US12545744B2 (en) 2026-02-10
US20140227279A1 (en) 2014-08-14
US20210040230A1 (en) 2021-02-11
KR20140067027A (ko) 2014-06-03
RU2014106933A (ru) 2015-09-20
CN104114184B (zh) 2017-04-19
US9879092B2 (en) 2018-01-30
AU2012294342B2 (en) 2017-07-27
CN104114184A (zh) 2014-10-22
CA2844668A1 (en) 2013-02-14
US20180094076A1 (en) 2018-04-05
WO2013023059A3 (en) 2013-04-04
CA2844668C (en) 2021-03-09
KR102221068B1 (ko) 2021-02-25

Similar Documents

Publication Publication Date Title
US12545744B2 (en) Anti-RhoB antibodies for the treatment of autoimmune and inflammatory diseases
US12247069B2 (en) Use of TGF-alpha polypeptide or anti-TGF-alpha antibodies for the treatment of diseases and disorders
US20230142697A1 (en) Glycan-Interacting Compounds and Methods of Use
JP7230819B2 (ja) 二重特異性抗体
CN104684931B (zh) 抗cd26抗体及其用途
JP2023514224A (ja) 自己免疫障害における抗ｂｃｍａ治療
US20230242674A1 (en) Compositions comprising antibodies to human ido-2
WO2015001010A1 (en) Human anti-il-32 antibodies
AU2018350372A1 (en) Method
AU2016298108B2 (en) Methods and compositions for the treatment of immunomodulatory diseases and disorders
CA2992145C (en) Methods and compositions for the treatment of immunomodulatory diseases and disorders
CN113004407B (zh) Lag3抗体及其应用

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20200810